2949-8198

ESMO Gastrointestinal Oncology

Elsevier

View prefix report (10.1016)

Health Score

0 Good

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Add abstracts to 293 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

High impact293 DOIs
2

Attach ORCID iDs across 103 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

Medium impact103 DOIs
3

Deposit reference lists for 32 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

Low impact32 DOIs

DOIs for this ISSN

Showing the top 5 of 293 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 Phase III trial of short-course radiotherapy followed by CAP… (10.1016/j.esmogo.2023.08.002)
Abstract ORCID
52.07 10
2 Clinical impact of circulating tumor DNA to track minimal re… (10.1016/j.esmogo.2024.100068)
Abstract ORCID
52.07 10
3 Recurrence monitoring using ctDNA in patients with metastati… (10.1016/j.esmogo.2023.100034)
Abstract ORCID
42.25 6
4 SAGA—a phase Ib/II single-arm, multicenter study of sacituzu… (10.1016/j.esmogo.2024.100051)
Abstract ORCID
34.95 4
5 Expanding the potential of antibody–drug conjugates in gastr… (10.1016/j.esmogo.2025.100154)
Abstract ORCID
34.95 4
6 The Liver Frailty Index predicts survival in systemic therap… (10.1016/j.esmogo.2024.100043)
Abstract ORCID
30.10 3
7 Exploring the associations between colorectal polyps and typ… (10.1016/j.esmogo.2024.100053)
Abstract ORCID
30.10 3
8 Real-world efficacy and toxicity data of paclitaxel and ramu… (10.1016/j.esmogo.2024.100073)
Abstract ORCID
30.10 3
9 High prevalence of NTRK fusions in sporadic dMMR/MSI mCRC RA… (10.1016/j.esmogo.2024.100084)
Abstract ORCID
30.10 3
10 Breath- and blood-based molecular assessment for gastroesoph… (10.1016/j.esmogo.2025.100132)
Abstract ORCID
30.10 3
11 Development and characterization of orthotopic patient-deriv… (10.1016/j.esmogo.2025.100133)
Abstract ORCID
30.10 3
12 GATA6 immunohistochemistry and prognosis after surgical rese… (10.1016/j.esmogo.2025.100138)
Abstract ORCID
30.10 3
13 Research training, barriers, and career development needs of… (10.1016/j.esmogo.2025.100208)
Abstract ORCID
30.10 3
14 A case of gastritis developing in a patient receiving zolbet… (10.1016/j.esmogo.2025.100216)
Abstract ORCID
30.10 3
15 Lymph node mapping-based optimal bowel-resection margin and… (10.1016/j.esmogo.2025.100231)
Abstract ORCID
30.10 3
16 Immune checkpoint inhibition (ICI) in current systemic thera… (10.1016/j.esmogo.2023.08.004)
Abstract
27.85 12
17 Clinical implementation of simultaneous multiple biomarkers… (10.1016/j.esmogo.2024.100086)
Abstract
27.85 12
18 Unleashing the power of anti-HER2 therapies in metastatic co… (10.1016/j.esmogo.2023.100032)
Abstract
26.98 11
19 Managing zolbetuximab-induced nausea and vomiting: a proposa… (10.1016/j.esmogo.2024.100128)
Abstract
26.03 10
20 Comparative efficacy of PD-1 blockade in patients with dMMR/… (10.1016/j.esmogo.2023.100037)
Abstract ORCID
23.86 2
21 Sidedness and addition of chemotherapy associated with treat… (10.1016/j.esmogo.2024.100052)
Abstract ORCID
23.86 2
22 BAYONET trial: staged combination with encorafenib, binimeti… (10.1016/j.esmogo.2024.100066)
Abstract ORCID
23.86 2
23 Current practices and challenges in implementing precision m… (10.1016/j.esmogo.2024.100074)
Abstract ORCID
23.86 2
24 Single-cell RNA sequencing of appendiceal adenocarcinoma rev… (10.1016/j.esmogo.2024.100094)
Abstract ORCID
23.86 2
25 Consensus guidance for prevention and management of nausea a… (10.1016/j.esmogo.2024.100131)
Abstract
23.86 8
26 CD147-expressed small extracellular vesicles enhance the det… (10.1016/j.esmogo.2025.100140)
Abstract ORCID
23.86 2
27 Optimising chemoradiotherapy in anal cancer (10.1016/j.esmogo.2025.100141)
Abstract ORCID
23.86 2
28 Total neoadjuvant therapy in early-onset versus average-onse… (10.1016/j.esmogo.2025.100170)
Abstract ORCID
23.86 2
29 Early bevacizumab dose and time modifications may affect eff… (10.1016/j.esmogo.2025.100186)
Abstract ORCID
23.86 2
30 Managing adverse events in patients with metastatic colorect… (10.1016/j.esmogo.2025.100191)
Abstract ORCID
23.86 2
31 Drug dose optimization and substitutions to improve access f… (10.1016/j.esmogo.2025.100239)
Abstract ORCID
23.86 2
32 ItaLynch: an ongoing Italian study to evaluate the feasibili… (10.1016/j.esmogo.2024.100044)
Abstract
22.58 7
33 Role of the microbiome in the development and treatment of g… (10.1016/j.esmogo.2024.100048)
Abstract
22.58 7
34 Gastric cancer hospital-based registry: real-world gastric c… (10.1016/j.esmogo.2024.100088)
Abstract
22.58 7
35 Temporal dynamics of CLDN18.2 expression following zolbetuxi… (10.1016/j.esmogo.2025.100206)
Abstract
22.58 7
36 Neoadjuvant immunotherapy for early-stage hepatocellular car… (10.1016/j.esmogo.2023.08.001)
Abstract
21.13 6
37 Higher rate of pathologic complete response in patients with… (10.1016/j.esmogo.2023.100033)
Abstract
21.13 6
38 Safety and efficacy of perioperative FLOT regimen in Japanes… (10.1016/j.esmogo.2024.100050)
Abstract
21.13 6
39 Second-line FOLFOX chemotherapy for patients with advanced b… (10.1016/j.esmogo.2024.100055)
Abstract
21.13 6
40 Early-onset colorectal cancer incidence in Norway: a nationa… (10.1016/j.esmogo.2024.100065)
Abstract
21.13 6
41 New perspectives in biliary tract cancers (10.1016/j.esmogo.2024.100092)
Abstract
21.13 6
42 TROPHIT1—a randomized, open-label, multicenter, phase II/III… (10.1016/j.esmogo.2024.100118)
Abstract
19.45 5
43 Palliative and supportive care underutilization for patients… (10.1016/j.esmogo.2024.100049)
Abstract
17.47 4
44 Safety and efficacy of first-line nivolumab plus chemotherap… (10.1016/j.esmogo.2024.100072)
Abstract
17.47 4
45 Gastrin-releasing peptide receptor expression in gastrointes… (10.1016/j.esmogo.2024.100105)
Abstract
17.47 4
46 Re-evaluating population-level screening recommendations to… (10.1016/j.esmogo.2025.100136)
Abstract
17.47 4
47 Hypoalbuminemia during zolbetuximab plus chemotherapy for cl… (10.1016/j.esmogo.2025.100257)
Abstract
17.47 4
48 ASCEND: a randomised, double-blinded, placebo-controlled, ph… (10.1016/j.esmogo.2023.07.001)
Abstract
15.05 3
49 Oligometastatic disease in esophagogastric cancer: an update… (10.1016/j.esmogo.2023.08.008)
Abstract ORCID
15.05 1
50 Codon-specific KRAS mutations predict survival in advanced p… (10.1016/j.esmogo.2023.100030)
Abstract
15.05 3